Table 1. Recent Therapies in Clinical Trials for Cardiac Amyloidosis.

Therapy	Number of participants	Outcome (survival/stabilization)	Primary trial findings
Tafamidis [73]	441	Improved survival and reduced cardiovascular-related hospitalizations	Effective in stabilizing transthyretin protein, slowing disease progression
Acoramidis [74]	632	Improved exercise capacity and quality of life	Superior stabilization of TTR tetramers, effective across various genetic forms of ATTR
Patisiran [75]	148	Improved cardiac markers and quality of life	Significant reduction in amyloid burden, though impact on mortality and hospitalization still under study
Vutrisiran [76]	122	Improved cardiac biomarkers and functional capacity	Promising results in reducing amyloid production and improving cardiac health

TTR: transthyretin; ATTR: amyloid transthyretin.